Entry |
|
Name |
Chronic arterial occlusive disease |
Subgroup |
Arteriosclerosis obliterans [DS: H01626] Buerger disease [DS: H01625] |
Description |
Chronic arterial occlusive disease is a highly prevalent peripheral vascular disorder. This disease is caused by arteriosclerosis obliterans (ASO), thromboangiitis obliterans (Buerger's disease), primary arterial thrombosis, embolism and so on. Of these, ASO is the most frequently encountered. Although differing clinically and pathologically, these diseases are similar in that they cause ischemia of tissues. The symptoms of chronic occlusive arterial disease result from impairment of blood flow to the extremities. Intermittent claudication is the commonest and usually the earliest symptom.
|
Category |
Vascular disease
|
Brite |
Human diseases [BR:br08402]
Cardiovascular diseases
Vascular diseases
H01629 Chronic arterial occlusive disease
Human diseases in ICD-11 classification [BR:br08403]
11 Diseases of the circulatory system
Diseases of arteries or arterioles
Chronic arterial occlusive disease
BD40 Atherosclerotic chronic arterial occlusive disease
H01629 Chronic arterial occlusive disease
BD41 Non-atherosclerotic chronic arterial occlusive disease
H01629 Chronic arterial occlusive disease
BD42 Raynaud phenomenon
H01629 Chronic arterial occlusive disease
|
Drug |
|
Comment |
See also H01625 Buerger's disease and H01626 Arteriosclerosis obliterans.
|
Other DBs |
|
Reference |
|
Authors |
JUERGENS JL |
Title |
Chronic occlusive arterial disease of the extremities. |
Journal |
|
Reference |
|
Authors |
Idei N, Nishioka K, Soga J, Hidaka T, Hata T, Fujii Y, Fujimura N, Maruhashi T, Mikami S, Teragawa H, Kihara Y, Noma K, Chayama K, Higashi Y |
Title |
Vascular function and circulating progenitor cells in thromboangitis obliterans (Buerger's disease) and atherosclerosis obliterans. |
Journal |
|
Reference |
|
Authors |
Lievre M, Morand S, Besse B, Fiessinger JN, Boissel JP |
Title |
Oral Beraprost sodium, a prostaglandin I(2) analogue, for intermittent claudication: a double-blind, randomized, multicenter controlled trial. Beraprost et Claudication Intermittente (BERCI) Research Group. |
Journal |
|